AERIO News in brief Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

被引：0
|
作者：
Cochereau, D.
Tredaniel, J.
机构：
来源：
ONCOLOGIE | 2013年 / 15卷 / 01期
关键词：
BEVACIZUMAB; GEMCITABINE;
D O I：
10.1007/s10269-013-2248-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：61 / 62
页数：2
相关论文
共 50 条
  • [1] Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
    Paz-Ares, Luis
    de Marinis, Filippo
    Dediu, Mircea
    Thomas, Michael
    Pujol, Jean-Louis
    Bidoli, Paolo
    Molinier, Olivier
    Sahoo, Tarini Prasad
    Laack, Eckart
    Reck, Martin
    Corral, Jesus
    Melemed, Symantha
    John, William
    Chouaki, Nadia
    Zimmermann, Annamaria H.
    Visseren-Grul, Carla
    Gridelli, Cesare
    LANCET ONCOLOGY, 2012, 13 (03): : 247 - 255
  • [2] Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
    Ciuleanu, Tudor
    Brodowicz, Thomas
    Zielinski, Christoph
    Kim, Joo Hang
    Krzakowski, Maciej
    Laack, Eckart
    Wu, Yi-Long
    Bover, Isabel
    Begbie, Stephen
    Tzekova, Valentina
    Cucevic, Branka
    Pereira, Jose Rodrigues
    Yang, Sung Hyun
    Madhavan, Jayaprakash
    Sugarman, Katherine P.
    Peterson, Patrick
    John, William J.
    Krejcy, Kurt
    Belani, Chandra P.
    LANCET, 2009, 374 (9699): : 1432 - 1440
  • [3] Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
    Middleton, Gary
    Gridelli, Cesare
    De Marinis, Filippo
    Pujol, Jean-Louis
    Reck, Martin
    Ramlau, Rodryg
    Parente, Barbara
    Pieters, Thierry
    Visseren-Grul, Carla M.
    San Antonio, Belen
    John, William J.
    Zimmermann, Annamaria Hayden
    Chouaki, Nadia
    Paz-Ares, Luis
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (05) : 865 - 871
  • [4] A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
    Nabil Mubarak
    Rabab Gaafar
    Samir Shehata
    Tarek Hashem
    Dani Abigeres
    Hamdy A Azim
    Gamal El-Husseiny
    Hamed Al-Husaini
    Zhixin Liu
    BMC Cancer, 12
  • [5] A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
    Mubarak, Nabil
    Gaafar, Rabab
    Shehata, Samir
    Hashem, Tarek
    Abigeres, Dani
    Azim, Hamdy A.
    El-Husseiny, Gamal
    Al-Husaini, Hamed
    Liu, Zhixin
    BMC CANCER, 2012, 12
  • [6] Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer
    Paz-Ares, Luis G.
    Altug, Sedat
    Vaury, Alexandra Thareau
    Corral Jaime, Jesus
    Russo, Francesca
    Visseren-Grul, Carla
    BMC CANCER, 2010, 10
  • [7] Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer
    Luis G Paz-Ares
    Sedat Altug
    Alexandra Thareau Vaury
    Jesús Corral Jaime
    Francesca Russo
    Carla Visseren-Grul
    BMC Cancer, 10
  • [8] Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Pujol, Jean-Louis
    Paz-Ares, Luis
    de Marinis, Filippo
    Dediu, Mircea
    Thomas, Michael
    Bidoli, Paolo
    Corral, Jesus
    San Antonio, Belen
    Chouaki, Nadia
    John, William
    Zimmermann, Annamaria
    Visseren-Grul, Carla
    Gridelli, Cesare
    CLINICAL LUNG CANCER, 2014, 15 (06) : 418 - 425
  • [9] PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)
    Paz-Ares, L. G.
    De Marinis, F.
    Dediu, M.
    Thomas, M.
    Pujol, J.
    Bidoli, P.
    Molinier, O.
    Sahoo, T. P.
    Laack, E.
    Reck, M.
    Corral, J.
    Melemed, S. A.
    John, W. J.
    Chouaki, N.
    Zimmerman, A.
    Grul, C. M. Visseren
    Gridelli, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)
    Paz-Ares, L. G.
    De Marinis, F.
    Dediu, M.
    Thomas, M.
    Pujol, J.
    Bidoli, P.
    Molinier, O.
    Sahoo, T. P.
    Laack, E.
    Reck, M.
    Corral, J.
    Melem, S. A.
    Grul, C. M. Visseren
    Gridelli, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
12345